Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis

Statin use in end-stage kidney disease (ESKD) patients are not encouraged due to low cardioprotective effects. Although the risk of hepatocellular carcinoma (HCC), a frequently occurring cancer in East Asia, is elevated in ESKD patients, the relationship between statins and HCC is not known despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyung Woo, Joo, Young Su, Kang, Shin Chan, Koh, Hee Byung, Han, Seung Hyeok, Yoo, Tae-Hyun, Kang, Shin-Wook, Park, Jung Tak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233705/
https://www.ncbi.nlm.nih.gov/pubmed/35752695
http://dx.doi.org/10.1038/s41598-022-14713-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233705/
https://www.ncbi.nlm.nih.gov/pubmed/35752695
http://dx.doi.org/10.1038/s41598-022-14713-w

Ejemplares similares